MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-06-2026
Mettler-Toledo International Retained Earnings 2011-2026 | MTD
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Mettler-Toledo International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.24 B | 8.37 B | 7.51 B | 6.73 B | 5.86 B | 5.1 B | 4.5 B | 3.94 B | 3.43 B | 3.07 B | 2.69 B | 2.36 B | 2.04 B | 1.75 B | 1.48 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.24 B | 1.48 B | 4.54 B |
Quarterly Retained Earnings Mettler-Toledo International
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.95 B | 8.74 B | 8.53 B | 8.37 B | 8.12 B | 7.91 B | - | 7.51 B | 7.33 B | 7.13 B | 6.91 B | 6.73 B | 6.46 B | - | 6.03 B | 5.86 B | 5.63 B | 5.43 B | 5.24 B | 5.1 B | 5.1 B | 5.1 B | 5.1 B | 4.5 B | 4.5 B | 4.5 B | 4.5 B | 3.94 B | 3.94 B | 3.94 B | 3.94 B | 3.43 B | 3.43 B | 3.43 B | 3.16 B | 3.07 B | 3.07 B | 3.07 B | 3.07 B | 2.69 B | 2.69 B | 2.69 B | 2.69 B | 2.36 B | 2.36 B | 2.36 B | 2.36 B | 2.04 B | 2.04 B | 2.04 B | 2.04 B | 1.75 B | 1.75 B | 1.75 B | 1.75 B | 1.48 B | 1.48 B | 1.48 B | 1.48 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.95 B | 1.48 B | 4.25 B |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
348 M | $ 112.78 | 0.68 % | $ 34.3 B |  USA |
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.13 | - | $ 4.89 M | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 16.31 | -0.12 % | $ 493 M | USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 74.22 | -1.99 % | $ 5.01 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
Medpace Holdings
MEDP
|
-460 M | $ 457.05 | 0.03 % | $ 13.2 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.59 | -1.61 % | $ 425 M | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-499 M | - | -6.19 % | $ 10.5 M | USA |
 |
Pacific Biosciences of California
PACB
|
-2.7 B | $ 1.37 | -1.8 % | $ 411 M | USA |
 |
Co-Diagnostics
CODX
|
4.6 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Precipio
PRPO
|
-98.2 M | $ 26.85 | -0.3 % | $ 34.8 M | USA |
 |
Personalis
PSNL
|
-550 M | $ 7.51 | -1.38 % | $ 445 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
RadNet
RDNT
|
-95.4 M | $ 59.53 | -3.58 % | $ 4.48 B | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 157.49 | -0.32 % | $ 7.81 B | USA |
 |
IQVIA Holdings
IQV
|
7.42 B | $ 164.98 | -1.19 % | $ 28.4 B | USA |
 |
Senseonics Holdings
SENS
|
-1.02 B | $ 6.58 | -0.6 % | $ 275 M | USA |
 |
Sotera Health Company
SHC
|
-532 M | $ 13.78 | -0.76 % | $ 3.91 B | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
-720 M | $ 1.21 | -17.47 % | $ 6.59 M | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 17.47 | -0.26 % | $ 391 M | USA |
 |
Neuronetics
STIM
|
-459 M | $ 1.54 | -4.06 % | $ 102 M | USA |
 |
Interpace Biosciences
IDXG
|
-235 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
IDEXX Laboratories
IDXX
|
6.39 B | $ 572.18 | -1.09 % | $ 46 B | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 124.58 | 0.64 % | $ 19.8 B | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 99.8 | -0.55 % | $ 8.23 B |  Irlanda |
 |
Guardant Health
GH
|
-2.99 B | $ 82.96 | -2.36 % | $ 10.4 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.45 B | - | - | $ 10.6 B |  Niderland |
 |
Twist Bioscience Corporation
TWST
|
-1.32 B | $ 44.3 | -0.45 % | $ 2.65 B | USA |
 |
Celcuity
CELC
|
-272 M | $ 100.81 | -5.57 % | $ 3.98 B | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 263.8 | -0.23 % | $ 21.9 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
ENDRA Life Sciences
NDRA
|
-103 M | $ 3.41 | -2.16 % | $ 1.83 M | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 7.9 | -2.47 % | $ 1.01 B | USA |
 |
Natera
NTRA
|
-1.94 B | $ 194.02 | -3.03 % | $ 19.1 B | USA |
 |
CareDx, Inc
CDNA
|
-735 M | $ 17.35 | -1.2 % | $ 925 M | USA |
 |
OPKO Health
OPK
|
-2.07 B | $ 1.14 | -1.3 % | $ 791 M | USA |